Foracort

# Foracort ## Overview - **Classification**: Inhaled Corticosteroid (ICS) + Long-Acting Beta2-Agonist (LABA) combination. - **Mechanism**: Budesonide (ICS) reduces airway inflammation. Formoterol (LABA) causes bronchodilation by relaxing airway smooth muscle. ## Primary Indications 1. **Asthma**: Maintenance treatment for patients not adequately controlled on ICS alone, or whose disease warrants both ICS and LABA. 2. **COPD**: Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease. ## Adult Dosing ### Standard Dosing **Asthma (Maintenance)** - **Dose**: **1-2 inhalations** of **80/4.5 mcg** or **160/4.5 mcg** (Budesonide/Formoterol) - **Frequency**: **Twice daily** (morning and evening) - **Route**: Oral inhalation - **Maximum**: **640 mcg Budesonide / 18 mcg Formoterol per day** (e.g., 2 inhalations of 160/4.5 mcg BID, or 4 inhalations of 80/4.5 mcg BID). **COPD (Maintenance)** - **Dose**: **1 inhalation** of **320/9 mcg** or **2 inhalations** of **160/4.5 mcg** (Budesonide/Formoterol) - **Frequency**: **Twice daily** - **Route**: Oral inhalation - **Maximum**: **640 mcg Budesonide / 18 mcg Formoterol per day**. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment needed. - **Hepatic Impairment**: Use with caution. Monitor for increased systemic corticosteroid effects due to budesonide's liver metabolism. - **Elderly Patients**: No specific dose adjustment needed. Monitor for cardiovascular effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Not indicated** for this combination product. ### Infants (1-12 months) - **Not indicated** for this combination product. ### Children (6-11 years) - **Indication**: Asthma (Maintenance) - **Dose**: **2 inhalations** of **80/4.5 mcg** (Budesonide/Formoterol) - **Frequency**: **Twice daily** - **Route**: Oral inhalation - **Maximum**: **160 mcg Budesonide / 9 mcg Formoterol per day** (i.e., 2 inhalations of 80/4.5 mcg BID). - **Special Notes**: Use a spacer for improved delivery and reduced local side effects. Monitor growth velocity. ### Adolescents (12-18 years) - **Indication**: Asthma (Maintenance) - **Dose**: Follow adult dosing. **1-2 inhalations** of **80/4.5 mcg** or **160/4.5 mcg** - **Frequency**: **Twice daily** - **Route**: Oral inhalation - **Maximum**: **640 mcg Budesonide / 18 mcg Formoterol per day**. - **Special Notes**: Ensure proper inhaler technique. ## Safety Information ### Contraindications - **Absolute**: Primary treatment of **status asthmaticus** or acute episodes of asthma/COPD requiring intensive measures. - **Absolute**: Severe hypersensitivity to budesonide, formoterol, or excipients. - **Relative**: Not for patients whose asthma is adequately controlled on low-dose inhaled corticosteroids alone (LABA monotherapy is contraindicated in asthma). ### Common Adverse Effects - **Very Common (>10%)**: Headache, nasopharyngitis. - **Common (1-10%)**: Oral candidiasis (thrush), throat irritation, cough, hoarseness, tremors, palpitations, nausea, muscle cramps, dizziness. - **Serious but Rare**: Severe paradoxical bronchospasm, hypersensitivity reactions (angioedema), pneumonia (in COPD patients), systemic corticosteroid effects (adrenal suppression, bone density decrease), cardiovascular events, hyperglycemia. ### Key Drug Interactions - **Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir)**: - **Effect and clinical significance**: Significantly increases systemic exposure to budesonide, increasing risk of systemic corticosteroid adverse effects. - **Monitoring requirement**: Avoid concomitant use. If unavoidable, monitor for Cushing's syndrome or adrenal suppression. - **Beta-blockers (non-cardioselective)**: - **Effect and clinical significance**: Can block formoterol's bronchodilatory effect, potentially causing severe bronchospasm. - **Monitoring requirement**: Avoid use in asthma unless no alternative. Use cardioselective beta-blocker with caution. - **QT-prolonging drugs (e.g., amiodarone, quinidine, TCAs)**: - **Effect and clinical significance**: Increased risk of ventricular arrhythmias with formoterol. - **Monitoring requirement**: Use with extreme caution. Monitor ECG. - **Diuretics (loop or thiazide)**: - **Effect and clinical significance**: May potentiate hypokalemia and ECG changes induced by beta-agonists. - **Monitoring requirement**: Monitor potassium levels, especially if severe hypokalemia risk. ## Monitoring & Follow-up - **Before Treatment**: Baseline pulmonary function (FEV1), assessment of inhaler technique. - **During Treatment**: - **Asthma/COPD control**: Symptoms, exacerbation frequency, rescue inhaler use, PEFR/FEV1 (periodically). - **Oral cavity**: Inspect for candidiasis. - **Children**: Monitor growth velocity (at least annually). - **Systemic effects**: Monitor for signs of adrenal suppression, bone mineral density, or ocular changes (cataracts, glaucoma) with high-dose/long-term use. - **Cardiovascular**: Monitor heart rate, blood pressure. - **Glucose**: Periodically monitor blood glucose in diabetic patients. - **Clinical Signs**: Worsening symptoms, increased rescue inhaler use, oral thrush, tremors, palpitations. ## Clinical Pearls - 💡 **Inhaler technique**: Crucial for effective drug delivery. Educate patients on proper use of the inhaler and encourage spacer use with MDIs, especially in children. - 💡 **Rinse mouth**: Advise patients to rinse mouth with water and spit after each dose to prevent oral candidiasis and minimize systemic absorption of budesonide. - 💡 **Not a rescue inhaler**: Emphasize that Foracort is a maintenance medication and should **NOT** be used for acute relief of bronchospasm. Patients require a separate short-acting beta-agonist (SABA) for rescue. - 💡 **Regular use**: Stress the importance of regular, twice-daily use even when feeling well, for optimal disease control. Do not stop abruptly. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.